1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Potassium Channel

Potassium Channel

KcsA

Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. They form potassium-selective pores that span cell membranes. Potassium channels are found in most cell types and control a wide variety of cell functions. Potassium channels function to conduct potassium ions down their electrochemical gradient, doing so both rapidly and selectively. Biologically, these channels act to set or reset the resting potential in many cells. In excitable cells, such asneurons, the delayed counterflow of potassium ions shapes the action potential. By contributing to the regulation of the action potential duration in cardiac muscle, malfunction of potassium channels may cause life-threatening arrhythmias. Potassium channels may also be involved in maintaining vascular tone.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-137986
    LUF7244
    Modulator 99.70%
    LUF7244 is a selective allosteric modulator of Kv11.1 channels. LUF7244 inhibits early afterdepolarizations. LUF7244 can be used for anti-arrhythmia research.
    LUF7244
  • HY-151891
    TASK-1-IN-1
    Inhibitor 98.36%
    TASK-1-IN-1 is a potent and selective TASK-1 (Potassium Channel) inhibitor with an IC50 of 148 nM. TASK-1-IN-1 shows a reduced inhibition of TASK-3 channels (IC50 of 1750 nM) and not a significant effect on other K+ channels. TASK-1-IN-1 has anticancer effects.
    TASK-1-IN-1
  • HY-155516
    KV1.3-IN-1
    Inhibitor 98.34%
    KV1.3-IN-1 (Compound trans-18) is a KV1.3 channel inhibitor (IC50: 230 nM and 26.12 nM in Ltk? cells and PHA-activated T-lymphocytes respectively). KV1.3-IN-1 impairs intracellular Ca2+ signaling. KV1.3-IN-1 inhibits T-cell activation, proliferation, and colony formation.
    KV1.3-IN-1
  • HY-W011641R
    (±)-Naringenin (Standard)
    Activator
    (±)-Naringenin (Standard) is the analytical standard of (±)-Naringenin. This product is intended for research and analytical applications. (±)-Naringenin is a naturally-occurring flavonoid. (±)-Naringenin displays vasorelaxant effect on endothelium-denuded vessels via the activation of BKCa channels in myocytes.
    (±)-Naringenin (Standard)
  • HY-100321
    MCHR1 antagonist 2
    Inhibitor 98.27%
    MCHR1 antagonist 2 is an antagonist of melanin concentrating hormone receptor 1, with an IC50 of 65 nM; MCHR1 antagonist 2 also inhibits hERG, with an IC50 of 4.0 nM in IMR-32 cells.
    MCHR1 antagonist 2
  • HY-162322
    VU0542270
    Inhibitor 98.48%
    VU0542270 is a selective vascular Kir6.1/SUR2B KATP channel inhibitor with an IC50 value of 100 nM. VU0542270 has an IC50 > 30 μM for the other nine members of the Kir channel family. VU0542270 can be used in the study of cardiovascular disease.
    VU0542270
  • HY-101422
    GAL-021
    Inhibitor 99.93%
    GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates.
    GAL-021
  • HY-106570
    Tripamide
    Inhibitor 98.78%
    Tripamide is an orally active sulfonamide-derived diuretic antihypertensive agent.
    Tripamide
  • HY-B0252S1
    Hydrochlorothiazid-13C,d2
    Activator 98.64%
    Hydrochlorothiazid-13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazid-<sup>13</sup>C,d<sub>2</sub>
  • HY-A0176
    Glisoxepide
    Inhibitor
    Glisoxepide, a sulphonamide derivative, is an orally available nonselective K(ATP) channel blocker, with antihyperglycemic activity and cardiovascular regulation effect.
    Glisoxepide
  • HY-A0135
    Enflurane
    Inhibitor ≥98.0%
    Enflurane, a volatile anaesthetic, is a potent inhibitor of high conductance Ca2+-activated K+ channels of Chara australis. Enflurane is an internal standard in monitoring halogenated volatile anaesthetics by headspace gas chromatography-mass spectrometry.
    Enflurane
  • HY-P3581
    PE 22-28
    Inhibitor 99.98%
    PE 22-28 is a TREK-1 inhibitor with IC50 value of 0.12 nM. PE 22-28 also is a 7 amino-acid peptide that is used as a core sequence for preparing analogs by chemical modifications and also by substitution of amino-acids. PE 22-28 can be used for the research of depression.
    PE 22-28
  • HY-P1409A
    ADWX 1 TFA
    Inhibitor 98.37%
    ADWX 1 TFA is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC50 value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 TFA ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 TFA can be used to study T cell-mediated autoimmune diseases.
    ADWX 1 TFA
  • HY-B0341S
    Nicorandil-d4
    Activator 99.81%
    Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases.
    Nicorandil-d<sub>4</sub>
  • HY-17412S1
    Minocycline-d6 sulfate
    Activator
    Minocycline-d6 sulfate is deuterated labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d<sub>6</sub> sulfate
  • HY-122024
    AZSMO-23
    Activator 99.87%
    AZSMO-23 is a potent hERG K+ channel activator. AZSMO-23 activats WT hERG pre-pulse and tail current with EC50 values of 28.6, 11.2 µM, respectively. AZSMO-23 has the potential for the research of long QT syndrome.
    AZSMO-23
  • HY-P4742A
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) (TFA)
    Inhibitor
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research.
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) (TFA)
  • HY-155516A
    cis-KV1.3-IN-1
    Inhibitor 99.19%
    cis-KV1.3-IN-1 (Compound cis-18) is a cis-isomer of KV1.3-IN-1 (HY-155516). cis-KV1.3-IN-1 is an inhibitor of the KV1.3 channel. cis-KV1.3-IN-1 (10 μM) inhibits KV1.3 by 25.53% in Xenopus oocytes expressing human hKV1.3.
    cis-KV1.3-IN-1
  • HY-B0753S
    Gliclazide-d4
    Inhibitor
    Gliclazide-d4 (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic.
    Gliclazide-d<sub>4</sub>
  • HY-17504A
    Rosuvastatin
    Inhibitor
    Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    Rosuvastatin
Cat. No. Product Name / Synonyms Application Reactivity